News

Take-Two Interactive Reports Strong Q2 Results
News

Take-Two Interactive Reports Strong Q2 Results

Take-Two Interactive reports strong Q2 results, exceeding earnings expectations and providing guidan...
4.3
Sphere Entertainment's Lack of Financial Guidance
News

Sphere Entertainment's Lack of Financial Guidance

Investors are disappointed as Sphere Entertainment fails to provide guidance on its fiscal year and...
4.6
U.S. Stock Markets Prepare to Open
News

U.S. Stock Markets Prepare to Open

With notable pre-market movements and market outlook, U.S. stock markets prepare to open. Get update...
4.3
E.ON Raises Investment Target
News

E.ON Raises Investment Target

E.ON raises its investment target for the full year, but faces challenges in its customer solutions...
4.6
Apple Stock Breaks Through Resistance
News

Apple Stock Breaks Through Resistance

Apple Inc.'s stock has experienced a strong rally, breaking through resistance and signaling a retur...
4.7
Hightower Expands its Portfolio with Acquisition of Resource Consulting Group
News

Hightower Expands its Portfolio with Acquisition of Resource Consulting Group

Hightower expands its portfolio by acquiring Resource Consulting Group, a renowned firm offering fee...
4.5
The Sluggish Housing Market: A Closer Look
News

The Sluggish Housing Market: A Closer Look

The sluggish housing market, at its slowest pace since the Great Recession, is driven by crucial lif...
4.3
Microsoft Stock on Pace for New All-Time High
News

Microsoft Stock on Pace for New All-Time High

Microsoft stock is experiencing remarkable growth and is on track to reach a new all-time closing hi...
4.8
Larry Culp's Leadership Journey: From Bridgewater to GE's Helm
News

Larry Culp's Leadership Journey: From Bridgewater to GE's Helm

Larry Culp's journey from Bridgewater to GE's CEO showcases his leadership abilities and commitment...
5.0
Ventyx Biosciences Halts Development of VTX958 for Autoimmune Diseases
News

Ventyx Biosciences Halts Development of VTX958 for Autoimmune Diseases

Ventyx Biosciences shares plummet as they halt development of VTX958 for autoimmune diseases, termin...
4.5